Specific Organisms and Therapeutic Regimens
Organism-specific therapeutic regimens for hospital-acquired pneumonia (HAP), health care–associated pneumonia (HCAP), and ventilator-associated pneumonia (VAP) are provided below, including those for Pseudomonas aeruginosa, Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible S aureus (MSSA), Legionella pneumophila, Acinetobacter baumannii, and Stenotrophomonas maltophilia. [1]
Definitions are as follows:
-
HAP: Diagnosis made more than 48 hours after admission
-
VAP: Diagnosis made 48-72 hours after endotracheal intubation
-
HCAP: Per the 2016 IDSA/ATS guidelines, this no longer is a subset of HAP, as isolated organisms are more consistent with CAP. Instead, individual risk factors for multidrug-resistant organisms (MDROs) should be assessed on a case-by-case basis.
Regimens for P aeruginosa pneumonia include the following:
-
Piperacillin/tazobactam 4.5 g IV q6h (standard infusion) or 4.5 g IV q8h (infused over 4 hours) or
-
Cefepime 2 g IV q8h or
-
Ceftazidime/avibactam 2.5 g (2 g ceftazidime, 0.5 g avibactam) IV q8h infused over 2 hours or
-
Imipenem/cilastatin 1 g q6-8h or
-
Meropenem 2 g IV q8h (standard infusion or infused over 3 hours) or
-
Cefiderocol 2 g IV q8h or
-
Aztreonam 2 g IV q8h or
-
Ceftolozane/tazobactam 3 g (2 g ceftolozane, 1 g tazobactam) infused over 1 hour (reserved for only carbapenem-resistant isolates) [2] or
-
Meropenem/vaborbactam 4 g IV (2 g meropenem, 2 g vaborbactam) q8h infused over 3 hours (reserved for only carbapenem-resistant isolates) or
-
Imipenem/cilastatin/relebactam 1.25 g IV q6h [3]
-
Duration of therapy: 7 days
-
Data are limited concerning the benefit of combination therapy for pseudomonal infections; when antimicrobial drug susceptibility results are known, it is reasonable to continue a single active beta-lactam agent and to discontinue the accompanying fluoroquinolone or aminoglycoside
-
For empiric therapy, an aminoglycoside (gentamicin 7 mg/kg/day IV, tobramycin 7 mg/kg/day IV, or amikacin 20 mg/kg/day IV) or fluoroquinolone (ciprofloxacin 400 mg IV q8h or levofloxacin 750 mg IV q24h) may be added for empiric coverage if organism resistance to local isolate is 10% or more as per local antibiogram or local resistance is unknown.
Regimens for K pneumoniae pneumonia include the following:
-
Ceftriaxone 2g IV q24h
-
Cefepime 2 g IV q8h or
-
Ceftazidime 2 g IV q8h or
-
Piperacillin-tazobactam 4.5 g IV q6h or
-
Cefiderocol 2 g IV q8h
Regimens for an extended-spectrum beta-lactamase (ESBL)–producing K pneumoniae strain include the following:
-
Imipenem/cilastatin 500 mg IV q6h or
-
Meropenem 1 g IV q8h or
-
Cefiderocol 2 g IV q8h or
-
Ceftolozane/tazobactam 3 g IV q8h or
-
Imipenem/cilastatin/relebactam 1.25 g IV q6h or
-
Ertapenem 1g q24h (if hemodynamically stable)
Regimens for carbapenem-resistant K pneumoniae (CRKP) strain pneumonia include the following:
-
Colistin 5 mg/kg/day IV divided q12h or
-
Polymyxin B 15,000-25,000 units/kg/day IV divided q12h (preferred over colistin) or
-
Consider addition of meropenem 2 g IV q8h to colistin or polymyxin (based on limited data) or
-
Imipenem/cilastatin/relebactam 1.25 g IV q6h or
-
Ceftazidime/avibactam 2.5 g (2 g ceftazidime, 0.5 g avibactam) IV q8h infused over 2 hours or
-
Meropenem-vaborbactam 4 g IV (2 g meropenem, 2 g vaborbactam) q8h infused over 3 hours; reserved for highly resistant organisms
-
Duration of therapy: 7 days
Regimens for MRSA pneumonia include the following:
-
Linezolid 600 mg IV or PO q12h for 7 days or
-
Vancomycin 15 mg/kg IV q12h for 7 days or
-
Telavancin 10mg/kg IV once daily for 7-21 days (reserved for use when alternative treatments are not suitable)
Regimens for MSSA pneumonia include the following:
-
Oxacillin 2 g IV q4h for 7 days or
-
Nafcillin 2 g IV q6h for 7 days (consider midline or peripherally inserted central catheter [PICC] owing to high incidence of phlebitis when given via peripheral intravenous [PIV] catheter) or
-
Cefazolin 2 g IV q8h for 7 days
-
Drugs listed for MRSA treatment may be used as alternatives if no beta-lactam drug is available
Regimens for L pneumophila pneumonia include the following:
-
Levofloxacin 750 mg IV q24h, then 750 mg/day PO for 7 days or
-
Moxifloxacin 400 mg IV or PO q24h for 7 days or
-
Azithromycin 500 mg IV q24h for 7 days
Regimens for A baumannii pneumonia include the following:
-
Sulbactam/durlobactam 2 g IV q6hr x 7-14 days or
-
Imipenem 1 g IV q6h or
-
Meropenem 2 g IV q8h (standard infusion or extended over 3 hours) or
-
Cefiderocol 2 g IV q8h or
-
Ampicillin/sulbactam 3 g IV q6h or
-
Tigecycline 100 mg IV in a single dose, then 50 mg IV q12h or
-
Minocycline 100 mg PO q12h or
-
Colistin 5 mg/kg/day IV divided q12h or
-
Polymyxin B 15,000-25,000 units/kg/day IV divided q12h
-
Duration of therapy: 14-21 days
Regimens for S maltophilia pneumonia include the following:
-
Trimethoprim/sulfamethoxazole 15-20 mg/kg/day of TMP IV or PO divided q8h or
-
Ciprofloxacin 750 mg PO or 400 mg IV q12h or
-
Moxifloxacin 400 mg PO or IV q24h
-
Duration of therapy: Uncertain, but usually 14 days or more